Preclinical Studies of Preactivated Merocyanine 540 and Merodantoin

  • Kirpal S. Gulliya
Part of the Medical Intelligence Unit book series (MIU.LANDES)


It is apparent from the discussion in the previous chapters that photoproducts in pMC540 display a significant toxicity against cultured tumor cells and enveloped viruses but are only minimally cytotoxic to normal cells. A question of obvious significance is whether these findings from in vitro studies have any relevance to cancer or viral infections in humans. In this chapter, we shall examine the data obtained from studies utilizing in vivo models that support further development of these compounds for ultimate clinical use.


Nude Mouse Breast Tumor Chemotherapeutic Agent Hypoxic Cell Athymic Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pervaiz S, Battaglino M, Matthews JL et al. Biodistribution and toxicity of photoproducts of merocyanine 540. Cancer Chemother Pharmacol 1993; 31: 467–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Roasli SB. Enzyme tests in diseases of the liver and hepatobiliary tract. In: Wilkinon J H, ed. The Principles and Practice of Diagnostic Enzymology. Chicago: Year Book, 1976: 3030–39.Google Scholar
  3. 3.
    Podolsky DK, Isselbacher KJ. Diagnostic procedures in liver disease. In: Harrison’s Principles of Internal Medicine. New York: McGraw-Hill, 1987: 1315–21.Google Scholar
  4. 4.
    Kahler S. Immunodeficiency syndrome makes cats desirable HIV model. J Amer Vet Med Assoc 1992; 20: 1674–75.Google Scholar
  5. 5.
    Wiggs RB, Lobprise HB, Matthews JL et al. Effects of preactivated MC540 in the treatment of lymphocytic plasmacytic stomatitis in feline leukemia virus and feline immunodeficiecy virus positive cats. J Veterinary Dentistry 1993; 10: 9–13.Google Scholar
  6. 6.
    Friedman MA. New directions for breast cancer therapeutic research. Hematol. Oncol. Clin. of North Amer 1994; 8: 113–19.Google Scholar
  7. 7.
    Arbuck SG, Dorr A, Friedman MA. Paclitaxel (Taxol) in breast cancer. Hematol Oncol Clin of North Amer 1994; 8: 121–38.Google Scholar
  8. 8.
    Mattem J, Bak M, Han EW, Volm M. Human tumor xenografts as model for drug testing. Cancer Metast Rev 1988; 7: 263–74.CrossRefGoogle Scholar
  9. 9.
    Rygaard J. History and pathology. In: Boven E, Winograd B, eds. The Nude Mouse in Oncology Research. Boca Raton: CRC Press, 1991: 1–11.Google Scholar
  10. 10.
    Chang P, Pervaiz S, Battaglino M et al. Synergy between preactivated photofrin-II and tamoxifen in killing retrofibroma, pseudomyxoma and breast cancer cells. Eur J Cancer 1991; 27: 1034–39.PubMedCrossRefGoogle Scholar
  11. 11.
    Patterson JS. “Novaldex” (tamoxifen) as an anticancer agent in humans. In: NonSteroidal Antiestrogens. Sydney: Academic Press, 1981: 453–72.Google Scholar
  12. 12.
    Patterson JS, Battersby LA. Tamoxifen: an overview of recent studies in the field of oncology. Cancer Treat Rep. 1980; 64: 775–78.PubMedGoogle Scholar
  13. 13.
    Shafie SM, Grantham FH. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic mice. J Natl Cancer Inst 1981; 67: 51–56.PubMedGoogle Scholar
  14. 14.
    Huseby RA, Maloney TM, McGrath CM. Evidence for a direct growth-stimulating effect of estradiol on human MCF-7 cells in vivo. Cancer Res 1984; 44: 2654–59.PubMedGoogle Scholar
  15. 15.
    Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem Mol Biol 1988; 20: 311–14.Google Scholar
  16. 16.
    Iino Y, Wolf DM, Langan-Fahey SM et al. Reversible control of oestradiol-stimulated growth of MCF-7 tumors by tamifoxen in the athymic mouse. Br J Cancer 1991; 64: 1019–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984; 44: 4006–10.PubMedGoogle Scholar
  18. 18.
    Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127–205.PubMedCrossRefGoogle Scholar
  19. 19.
    Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Adv Cancer Res 1978; 28: 149–250.PubMedCrossRefGoogle Scholar
  20. 20.
    Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1979; 38: 2651–60.Google Scholar
  21. 21.
    Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980; 283: 139–46.PubMedCrossRefGoogle Scholar
  22. 22.
    Nicolson GL. Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochem Biophys Acta 1988; 948: 175–24.PubMedGoogle Scholar
  23. 23.
    Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636–49.PubMedGoogle Scholar
  24. 24.
    Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986; 55: 1037–57.PubMedCrossRefGoogle Scholar
  25. 25.
    Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1987; 233: 467–70.CrossRefGoogle Scholar
  26. 26.
    Reich R, Thompson EW, Iwamoto Y et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48: 3307–12.PubMedGoogle Scholar
  27. 27.
    Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by recombinant human tissue inhibitor of metyalloproteases. J Natl Cancer Inst 1990; 82: 589–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Gehlsen KR, Argraves WS, Pierschbacher MD et al. Inhibition of in vitro tumor invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol 1988; 106: 925–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Kumagai H, Tajima M, Ueno Y et al. Effect of cyclic RGD peptide on cell adhesion and tumor metastasis. Biochem Biophys Res Commun 1991; 177: 74–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Bitonti Aj, Dumont JA, Bush TL et al. Regression of human breast tumor xenografts in response to (E)-2’-Deoxy-2’ (fluoromethylene) cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 1994; 54: 1485–90.PubMedGoogle Scholar
  31. 31.
    Bush RS, Jenkin RDT, Allt W et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978; 37: 302–6.Google Scholar
  32. 32.
    Gatenby RA, Kessler HB, Rosenblum JS et al. Oxygen distribution in squamous cell carcinoma metastases: relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14: 831–38.PubMedCrossRefGoogle Scholar
  33. 33.
    Tannock I. Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation. Cancer Res 1982; 42: 4921–26.PubMedGoogle Scholar
  34. 34.
    Coleman CN. Hypoxia in tumors: a paradigm for the approach to biochemical and physiological heterogeniety. J Natl Cancer Inst 1988; 80: 310–17.PubMedCrossRefGoogle Scholar
  35. 35.
    Gray LH, Conger AD, Ebert M. The concentration of oxygen dissolved in tissues at the time of radiation as a factor of radiotherapy. Br J Radiol 1953; 26: 638–48.PubMedCrossRefGoogle Scholar
  36. 36.
    Thomlinso RH, Gray LH. The histological structure of some human lung cancer and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539–49.CrossRefGoogle Scholar
  37. 37.
    Brown JM. Evidence for acutely hypoxic cells in mouse tumors and a possible mechanism of reoxygenation. Br J Radiol 1979; 52: 650–55.PubMedCrossRefGoogle Scholar
  38. 38.
    Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10: 695–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Carter DB, Silver IA. Quantitative measurements of oxygen tension in normal tissues and in tumor of patients before and after radiotherapy. Acta Radiol 1960; 53: 233–56.CrossRefGoogle Scholar
  40. 40.
    Yuhas JM, Storer JB. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 1969; 42: 331–35.PubMedGoogle Scholar
  41. 41.
    Denekamp J, Harris SR Tests of two electron affinic radiosensitizers in vivo using regrowth of an experimental carcinoma. Radiat Res 1975; 61: 191–203.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Kirpal S. Gulliya
    • 1
    • 2
    • 3
  1. 1.Baylor Research InstituteBaylor University Medical CenterDallasUSA
  2. 2.Institute of Biomedical StudiesBaylor UniversityWacoUSA
  3. 3.Department of Biological ScienceUniversity of North TexasDentonUSA

Personalised recommendations